Looking for Affordable Office & Start-Up Space on the South Boston Waterfront? CLICK HERE

 ~Boston's Innovation District News, Technology & Special Events~

Boston Innovation District News – Acetylon Pharmaceuticals Move In

Acetylon moving to Boston’s Seaport Center

Article Courtesy of:  www.masshightech.com

Biotech Acetylon Pharmaceuticals Inc. is moving from its Albany Street location in Boston to the Seaport Center near the South Boston waterfront.

Acetylon is developing selective small molecule histone deacetylase (HDAC) inhibitors and other targeted drugs for the treatment of cancers, and for inflammatory, neurodegenerative, genetic and infectious diseases.

The company has leased 9,700 square feet of space for its new headquarters, including office and lab space, as well as two biosafety level 2 labs that are scheduled to be completed this summer. According to realtor Jones Lang LaSalle, which represented the property owner Beal Companies, Acetylon is the first R&D tenant in Seaport Center.

The news came just a week after Acetylon bumped up its Series B funding to $27 million, and closed the round short of its initial stated goal of $30 million.

Innovation District lures another drug company

By Donna Goodison  |   Tuesday, July 5, 2011  |  http://www.bostonherald.com

Another pharmaceutical company is headed to the Innovation District in South Boston.

Acetylon Pharmaceuticals will relocate to Seaport Center Boston, where it will lease 9,700 square feet of headquarters and lab space, according to Jones Lang LaSalle, the property’s leasing agent.

Acetylon is developing small molecule drugs to treat cancer, autoimmune and other diseases. Its new location will include research and development lab space and two Biosafety Level 2 labs. Construction on the second-floor space is expected to be finished this summer.

The company is relocating to the Fargo Street building from Boston’s Albany Street.

Article URL: http://www.bostonherald.com/business/healthcare/view.bg?articleid=1349819

Related Articles:

The Ticker

Cambridge’s Brightcove moving to Atlantic Wharf in Hub

About Acetylon Pharmaceuticals

Acetylon Pharmaceuticals Inc. is developing next-generation selective small molecule histone deacetylase (HDAC) inhibitors and other targeted drugs for the treatment of cancers as well as inflammatory, neurodegenerative, genetic and infectious diseases.
Selective HDAC inhibitors have the potential to reduce or eliminate the substantial side effects observed with current non-selective approaches while also realizing their extraordinary potential for enhanced therapeutic benefit through higher dosing, extended administration and reduction of combination drug toxicity. Selective HDAC inhibitors also have potential for improved therapeutic benefit in autoimmune and other inflammatory disorders, neurodegenerative diseases and certain genetic and infectious diseases.

Speak Your Mind

Related Websites:

  • Twitter
  • Facebook
  • Flickr
  • YouTube

Created by: Media Crush Salem MA